MX1 and myeloid sarcoma: The objective of our study was to evaluate if baseline MxA expression has a role in predicting the response to IFN-β treatment while in Van der Voort study [26] the main objective was to evaluate if MxA is related to clinical disease activity in early MS untreated patients.